FIELD: medicine. SUBSTANCE: preparation is a mixture of substances involving interleukin-2 at concentration 1 wt.-% not above, bioactive cytokines at concentrations corresponding natural ratio, mixture of α- and b-chains of hemoglobin, impurities of nonidentified structure prepared from mammal mononuclear blood cells by their stimulation with activating addition of Ca-ionophore (concentration is 1-1000 ng/ml) and phorbol-12-myristate-13-acetate (concentration is 1-100 ng/ml) followed by cultivation and isolation from supernatant by a single step of liquid chromatography. Preparation can contain fetuin (concentration is 0.5-10 wt.-%) in the case of addition of activating additions of fetal serum to the composition. Preferable cell concentration in cultural fluid is 0.5-10 mln/ml, desirable cultivation time is 1-120 hr. Eluent used at liquid chromatography is 0.01 M trifluoroacetic acid solution or 15, 30 and 60% acetonitrile solution in 0.01 M aqueous trifluoroacetic acid solution. After separation of supernatant mononuclear cells were preferably to be stimulated repeatedly with activating additions. Proposed preparation shows the following advantages: high immunomodulating activity, the presence of natural carriers (a- and b -chains of hemoglobin), multicomponent nature of preparation excludes the necessity of selection and addition of recombinant cytokines, simple technology of preparing, absence of antibiotics in the process of its preparing that increases raw activity, possibility for repeated use of mononuclear cells. EFFECT: enhanced quality of preparation. 6 cl, 5 dwg
Title | Year | Author | Number |
---|---|---|---|
METHOD OF PREPARING SUBSTANCE SHOWING IMMUNOSTIMULATING, ANTIVIRAL AND ANTIBACTERIAL ACTIVITY, SUBSTANCE OBTAINED BY THIS METHOD AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 2001 |
|
RU2195308C1 |
METHOD FOR PREPARING ACTIVATED MONONUCLEAR LEUKOCYTES | 2009 |
|
RU2402338C1 |
METHOD OF SELECTING MEDICINAL PRODUCTS FOR PHARMACOLOGICAL INDUCTION OF MITOCHONDRIAL DYSFUNCTION IN MACROPHAGES FOR ANTITUMOR THERAPY | 2023 |
|
RU2810558C1 |
METHOD OF CYTOGENETIC ACTIVATION OF HUMAN LYMPHOCYTES | 2015 |
|
RU2603079C2 |
DRUG OF HUMIC NATURE, WHICH HAS AN IMMUNOMODULATORY EFFECT | 2022 |
|
RU2783772C1 |
CULTIVATION METHOD AND CULTURAL MEDIUM FOR PROLIFERATION OF HUMAN Vγ9Vδ2 T-CELLS | 2019 |
|
RU2791182C2 |
AGENT HAVING IMMUNOMODULATORY ACTIVITY | 2018 |
|
RU2697526C1 |
IMMUNOMODULATING HUMIC AGENT | 2020 |
|
RU2756353C1 |
METHOD OF DETECTING OF SPECIFICITY ACTIVATED LYMPHOCYTES AND ENVIRONMENT FOR ITS REALISATION | 2004 |
|
RU2343486C2 |
MEANS OF IMMUNOMODULATING ACTIVITY | 2017 |
|
RU2657819C1 |
Authors
Dates
1995-11-27—Published
1993-07-06—Filed